Overview

A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of VX-864 in participants with the PiZZ genotype over 48 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated